What is the 13F Pro Quality Score for AXGN?

13F Pro ranks Axogen, Inc. (AXGN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AXGN's current score at https://13fpro.ai/research/AXGN (free sign-up required for the full ranking).

Which hedge funds own the most AXGN stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AXGN include First Light Asset Management,, BlackRock,, MORGAN STANLEY. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/AXGN as soon as new 13F filings post.

Where does 13F Pro source AXGN data?

All Axogen, Inc. fundamentals and ownership data come directly from SEC EDGAR. Axogen, Inc. files with the SEC under CIK 805928. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AXGN in?

Axogen, Inc. (AXGN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AXGN research updated on 13F Pro?

AXGN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Axogen, Inc.(AXGN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 805928 AXGN stock profile & AI dashboard →

13F Pro Quality Score

38.0/100

Rank #2,028 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

80.8/100

Profitability

21.4/100

Balance Sheet

17.5/100

Earnings Quality

30.0/100

Free Cash Flow

27.6/100

Institutional Flow

95.1/100

Revenue Scale

25.7/100

Dilution Risk

13.6/100

AXGN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Axogen, Inc. (AXGN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AXGN at 38.0/100 on a 32-signal composite quality model, placing it at rank #2,028 of 2,879 stocks — the bottom half of the AI-ranked universe. AXGN scores in the top quartile across institutional flow (95.1), revenue growth (80.8). Areas of concern include balance sheet strength (17.5) and profitability (21.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Axogen, Inc. reports quarterly revenue of $61.5M, net income of $-19.6M, an operating margin of -4.6%. Top institutional holders of AXGN by reported 13-F value include First Light Asset Management,, BlackRock,, MORGAN STANLEY, based on the most recent SEC filings. AXGN trades on the Nasdaq exchange and files with the SEC under CIK 805928. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AXGN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Axogen, Inc. directly from SEC EDGAR. Axogen, Inc.'s 13F Pro composite quality score has ranged between 8 and 64 since 2021, currently 38.0 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about Axogen, Inc.

Quirks, history, and lore behind AXGN — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical device company · small-cap · listed on Nasdaq · headquartered in Florida.
2
The Numbers
Annual revenue in the range of $150–200 million — not a giant, but it occupies a near-monopoly niche where very few rivals dare to tread.
3
The History
Founded in the early 2000s, it was built around a specific type of surgical repair technology that had been largely ignored by the big medical-device players.
4
The Secret
Its entire business is focused on peripheral nerve repair — helping surgeons reconnect or bridge damaged nerves after trauma or surgery, a problem affecting millions of patients a year.
5
The Lore
Its flagship products include nerve grafts and nerve conduits processed from human donor tissue, making it one of the few pure-play companies in neural regeneration.
6
The Giveaway
The name literally spells out its mission: axon + regeneration, and its ticker is just as on-the-nose for a company that fixes damaged nerves one surgery at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$61.5M

Net Income

Q1 2026

$-19.6M

Free Cash Flow

Q1 2026

$-1.2M

Operating Margin

Q1 2026

-4.6%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+17.8% YoY

$187.3MFY 2024

FY21 $127.4MFY22 $138.6MFY23 $159.0MFY24 $187.3M

Net Income

+54.1% YoY

$-10.0MFY 2024

FY21 $-27.0MFY22 $-28.9MFY23 $-21.7MFY24 $-10.0M

Operating Income

+84.7% YoY

$-3.3MFY 2024

FY21 $-25.4MFY22 $-29.7MFY23 $-21.5MFY24 $-3.3M

EPS (Diluted)

+54.9% YoY

$-0.23FY 2024

FY21 $-0.65FY22 $-0.69FY23 $-0.51FY24 $-0.23

Total Assets

+3.5% YoY

$203.7MFY 2024

FY21 $208.0MFY22 $195.4MFY23 $196.8MFY24 $203.7M

Total Debt

+1.9% YoY

$47.5MFY 2024

FY21 $44.8MFY22 $45.7MFY23 $46.6MFY24 $47.5M

Op. Cash Flow

+179.3% YoY

$4.5MFY 2024

FY21 $-13.4MFY22 $-16.1MFY23 $-5.7MFY24 $4.5M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019	FY 2017
Revenue	$187.3M +17.8%	$159.0M +14.7%	$138.6M +8.8%	$127.4M +19.3%	$106.7M +76.6%	$60.4M
Net Income	$-10.0M +54.1%	$-21.7M +25.0%	$-28.9M -7.3%	$-27.0M +7.4%	$-29.1M -178.9%	$-10.4M
Operating Income	$-3.3M +84.7%	$-21.5M +27.8%	$-29.7M -16.9%	$-25.4M +19.1%	$-31.4M -295.0%	$-8.0M
EPS (Diluted)	$-0.23 +54.9%	$-0.51 +26.1%	$-0.69 -6.2%	$-0.65 +12.2%	$-0.74	—
Total Assets	$203.7M +3.5%	$196.8M +0.7%	$195.4M -6.1%	$208.0M +34.5%	$154.6M +162.7%	$58.9M
Total Debt	$47.5M +1.9%	$46.6M +1.9%	$45.7M +2.0%	$44.8M +2481.9%	$1.7M -91.6%	$20.5M
Operating Cash Flow	$4.5M +179.3%	$-5.7M +64.4%	$-16.1M -19.9%	$-13.4M +32.5%	$-19.9M -115.1%	$-9.2M

AI Insight: AXGN Financial Trends

Revenue grew 25% year-over-year to $61M in Q1 2026, but profitability deteriorated with net income dropping to -$20M from +$1M in prior quarters.

• Revenue accelerated from $49M in Q1 2025 to $61M in Q1 2026, representing 25% year-over-year growth.

• Net income plunged to -$20M in Q1 2026 from +$1M in Q2-Q3 2025, marking significant profitability deterioration.

• Total debt eliminated entirely in Q1 2026, dropping from $48M to $0M while equity surged to $245M.

⚠ Operating cash flow turned volatile, swinging from -$13M in Q1 2025 to positive territory before settling at $2M.

⚠ Operating income inconsistency with -$3M in Q1 2026 despite revenue growth, signaling margin pressure or one-time costs.

AI Insight: AXGN Ratio Trends

Axogen deteriorated sharply in Q4 2025 with operating margin collapsing to -16.3% after three quarters of positive profitability.

• Operating margin swung from 3.2% in Q3 2025 to -16.3% in Q4 2025, marking a dramatic reversal.

• Net profit margin plunged from 1.2% in Q3 2025 to -22.0% in Q4 2025.

• Debt-to-equity ratio improved steadily from 0.49 in Q2 2024 to 0.00 in Q1 2026.

⚠ ROIC crashed from 4.5% in Q3 2025 to -22.1% in Q4 2025, signaling severe capital efficiency breakdown.

⚠ Q1 2026 margins remain deeply negative despite some recovery from Q4 2025 lows.

Get alerted when AXGN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Axogen, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AXGN

First Light Asset Management, LLC
$132.6M4,002,768 sh
BlackRock, Inc.
$128.2M3,870,851 sh
MORGAN STANLEY
$103.5M3,122,982 sh
VANGUARD CAPITAL MANAGEMENT LLC
$75.9M2,291,563 sh
ArrowMark Colorado Holdings LLC
$63.5M1,915,439 sh
WASATCH ADVISORS LP
$61.5M1,857,350 sh
Polar Capital Holdings Plc
$49.7M1,500,822 sh
Assenagon Asset Management S.A.
$45.8M1,381,263 sh
FMR LLC
$43.5M1,314,020 sh
GEODE CAPITAL MANAGEMENT, LLC
$40.4M1,220,141 sh

Fund	Value	Shares
First Light Asset Management, LLC	$132.6M	4,002,768
BlackRock, Inc.	$128.2M	3,870,851
MORGAN STANLEY	$103.5M	3,122,982
VANGUARD CAPITAL MANAGEMENT LLC	$75.9M	2,291,563
ArrowMark Colorado Holdings LLC	$63.5M	1,915,439
WASATCH ADVISORS LP	$61.5M	1,857,350
Polar Capital Holdings Plc	$49.7M	1,500,822
Assenagon Asset Management S.A.	$45.8M	1,381,263
FMR LLC	$43.5M	1,314,020
GEODE CAPITAL MANAGEMENT, LLC	$40.4M	1,220,141

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AXGN on your watchlist

Track score changes the day Axogen, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AXGN a good stock to buy?

13F Pro's AI-powered analysis of Axogen, Inc. (AXGN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AXGN are available on the AXGN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AXGN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AXGN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Axogen, Inc.'s investment landscape.